Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SIL 204

Next Previous
Drug Profile

SIL 204

Alternative Names: KRASG12D-LODER; siG12D-LODER; SIL-204

Latest Information Update: 14 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silenseed
  • Developer Silexion Therapeutics
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action KRAS protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Colorectal cancer; Lung cancer

Most Recent Events

  • 09 Jul 2025 Pharmacodynamics data from a preclinical trial in Lung Cancer released by Silexion Therapeutics
  • 09 Jul 2025 Silexion Therapeutics plans a phase II/III trial for Pancreatic cancer (Late-stage disease, Adjunctive therapy) in the second quarter of 2026
  • 29 May 2025 Pharmacodynamics data from a preclinical trial in Pancreatic cancer, Colorectal cancer, and Lung Cancer released by Silexion Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top